For how long is a QuantiFERON‑TB Gold interferon‑γ release assay result considered valid for clinical decision‑making?

How Long is a QuantiFERON Gold Test Valid?

A QuantiFERON-TB Gold test result does not have a defined expiration date for clinical validity—the result reflects infection status at the time of testing and remains valid indefinitely unless new TB exposure occurs or clinical circumstances change. 1

Key Clinical Scenarios

For Routine Screening (No Recent Exposure)

• Negative results in healthy adults without recent TB contact are considered valid and do not require repeat testing unless:

  • New TB exposure occurs
  • The person develops symptoms suggestive of TB disease
  • Serial testing is required (e.g., healthcare workers in high-risk settings)

• Positive results remain positive and indicate TB infection requiring evaluation for active disease and consideration of latent TB treatment 1

For Recent TB Contacts (Critical Exception)

If someone has recent contact with infectious TB, a negative QuantiFERON result must be repeated 8-10 weeks after the end of exposure 1. This mirrors TST recommendations and accounts for the "window period" when infection may be present but not yet detectable.

The evidence shows:

• IGRA conversion typically occurs 4-7 weeks after exposure, though it can occur as late as 14-22 weeks 2
• Recent research suggests the optimal repeat testing time is approximately 10 weeks following exposure 3

Special Populations Requiring Window Period Testing

For high-risk contacts (children <5 years or severely immunocompromised persons exposed to highly contagious TB):

• Begin presumptive LTBI treatment immediately ("window period prophylaxis")
• Repeat QuantiFERON 8-10 weeks after contact ends
• Consider completing full treatment course even if repeat test is negative when transmission rate was high or false-negative is suspected 1

Important Caveats

Test Variability and Reproducibility

• QuantiFERON shows within-subject variability of ±60-70% in IFN-γ responses over short periods 4
• Results near the cutoff threshold are less reproducible
• In low-risk populations undergoing serial screening, cumulative false-positive rates can reach 27.4% after 7 years of annual testing 5

Indeterminate Results

• 10% of tests yield indeterminate results, primarily due to low mitogen response 6
• More common in patients with:
  • Severe COVID-19 (OR 3.9)
  • Pharmacological immunosuppression (OR 1.7)
  • Severe lymphopenia (OR 1.7)
  • Hospitalization (OR 3.9) 6
• Repeat testing with fresh specimen or consider TST for persons with high likelihood of infection 1

Monitoring Treatment

Do not use QuantiFERON to monitor response to LTBI treatment—87.5% of patients remain positive after 3 months of therapy and 84.6% after 15 months, with no significant change in IFN-γ levels 7. The test detects immunologic memory, not active infection.

Practical Algorithm

1. Initial negative result + no TB exposure → Valid indefinitely; no repeat needed
2. Initial negative result + recent TB contact → Repeat at 8-10 weeks post-exposure
3. Initial positive result → Evaluate for active TB; if excluded, treat LTBI; result remains valid
4. Indeterminate result + high TB risk → Repeat QuantiFERON or perform TST
5. Indeterminate result + low TB risk → No further testing needed

The 2005 CDC guidelines 1 remain the authoritative source, emphasizing that QuantiFERON timing should follow the same principles as TST until more specific data become available.